Clinical Context
Henrik — MDS-AML / Post-HSCT
Born Nov 1989 (age 36). MDS-AML, allogeneic HSCT Nov 2023 (age 34).
Multi-organ chronic GvHD. Ruxolitinib 10mg BID from Mar 2026.
HEV diagnosed Mar 2026. Oura Gen 4.
Mitch — Childhood ALL Survivor + Post-Stroke
Born Sept 1989 (age 36). ALL at 14 (likely anthracyclines, vincristine).
Bilateral carotid/vertebral dissection with stroke at 33 (left main).
20+ yrs late effects: cardiotoxicity, autonomic neuropathy. Oura Gen 3.
Shared Clinical Profile
Both hematologic cancer survivors (ALL vs MDS-AML). Both treated with anthracyclines
(Mitch as child, Henrik as adult with idarubicin). Both with subsequent neurovascular/neuroimmunologic
complications. Same age (2 months apart). Both with elevated resting HR and autonomic dysfunction
via different mechanisms: Mitch from accumulated cardiotoxicity + stroke; Henrik from GvHD +
immunosuppression.